PubMed ID: 29275147 Author(s): Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC Jr, Greven CM; ACCORD Study Group. Lack of longitudinal association between thiazolidinediones and incidence and progression of …
Matthew Davis
The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study.
PubMed ID: 25172198 Author(s): Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT; Action to Control Cardiovascular Risk in Diabetes Eye Study …
Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36.
PubMed ID: 24385141 Author(s): Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Davis MD, Ferris FL 3rd; Age-Related Eye Disease Study Research Group. Ten-year follow-up of age-related macular degeneration in the Age-Related Eye …
Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.
PubMed ID: 23582353 Author(s): Chew EY, Clemons TE, Agrón E, Sperduto RD, Sangiovanni JP, Kurinij N, Davis MD; Age-Related Eye Disease Study Research Group. Long-term effects of vitamins C and E, β-carotene, and zinc on …
Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity.
PubMed ID: 23615341 Author(s): Gangaputra S, Lovato JF, Hubbard L, Davis MD, Esser BA, Ambrosius WT, Chew EY, Greven C, Perdue LH, Wong WT, Condren A, Wilkinson CP, Agrón E, Adler S, Danis RP; ACCORD …
The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
PubMed ID: 23404115 Author(s): Sheetz MJ, Aiello LP, Davis MD, Danis R, Bek T, Cunha-Vaz J, Shahri N, Berg PH; MBDL and MBCU Study Groups. The effect of the oral PKC β inhibitor ruboxistaurin on …
Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
PubMed ID: 21862954 Author(s): Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD, Wolka AM, Shahri N, Milton RC; PKC-DRS and PKC-DRS2 Study Groups. Oral protein kinase c β inhibition using ruboxistaurin: …
Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus.
PubMed ID: 21571677 Author(s): Gangaputra S, Almukhtar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of …
Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
PubMed ID: 21386766 Author(s): Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP; Mbdv Study Group. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution …